5AM Venture Management, LLC

In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), 5AM Venture Management, LLC reported 31 stock positions worth $419.1 million. Its top holding was Entrada Therapeutics (TRDA) at 18.2% of the portfolio, followed by Enliven Therapeutics (ELVN, 8.8%) and Skye Bioscience (SKYE, 6.7%). Compared with Q3 2024, it opened 4 new positions, sold out of 1 and reduced 6. The biggest buy was a new position in CAMP4 Therapeutics (CAMP) and the biggest sale Dianthus Therapeutics (DNTH, shares −17%).

Most Recent 13F
Q2 2026
Location
SAN FRANCISCO, CA
CIK
0001799883
Portfolio Value
$419.1M (Q4 2024)
SEC Filing
0001085146-25-001687 ↗ filed Feb 14, 2025

Holdings Value

0$100.0M$200.0M$300.0M$400.0M$500.0M Q1 2024: $446.6M Q1 2024 Q2 2024: $447.1M Q2 2024 Q3 2024: $484.0M Q3 2024 Q4 2024: $419.1M $419.1M Q4 2024 Q1 2025: $264.4M Q1 2025 Q2 2025: $260.1M Q2 2025 Q3 2025: $273.0M Q3 2025 Q4 2025: $318.1M Q4 2025 Q1 2026: $360.2M Q1 2026 Q2 2026: $287.9M Q2 2026

Holdings 31 stocks · $419.1M
TRDA Entrada Therapeutics Inc. 18.19% 4,408,379 $76.2M No change
ELVN Enliven Therapeutics Inc. 8.75% 1,629,765 $36.7M Reduce -7.0%
SKYE Skye Bioscience Inc. 6.69% 9,913,168 $28.1M No change
TECX Tectonic Therapeutic Inc. 6.57% 596,660 $27.5M Reduce -7.7%
ARTV Artiva Biotherapeutics Inc. 5.66% 2,353,304 $23.7M No change
DNTH Dianthus Therapeutics Inc. 5.35% 1,027,711 $22.4M Reduce -16.6%
BHVN Biohaven Ltd. 4.27% 478,972 $17.9M No change
PHVS Pharvaris NV 3.65% 797,600 $15.3M No change
MLTX Moonlake Immunotherapeutics 3.65% 282,313 $15.3M No change
CAMP CAMP4 Therapeutics Corp. 3.65% 2,927,915 $15.3M New
VRDN Viridian Therapeutics Inc. 3.37% 736,595 $14.1M No change
CNTA Centessa Pharmaceuticals Ltd. 3.32% 830,945 $13.9M Reduce -35.3%
ERAS Erasca Inc. 3.24% 5,405,404 $13.6M No change
PRAX Praxis Precision Medicines I 3.12% 170,000 $13.1M Reduce -50.0%
TYRA Tyra Biosciences Inc. 3.12% 939,298 $13.1M No change
CLDX Celldex Therapeutics Inc. 3.00% 497,270 $12.6M No change
EYPT Eyepoint Inc. 1.87% 1,050,000 $7.8M No change
VKTX Viking Therapeutics Inc. 1.82% 189,593 $7.6M Reduce -20.2%
VOR Vor Biopharma Inc. 1.69% 6,361,723 $7.1M No change
ANAB Anaptysbio Inc. 1.13% 357,733 $4.7M No change
AKRO Akero Therapeutics Inc. 1.10% 165,000 $4.6M New
SCPH Scpharmaceuticals Inc. 1.01% 1,200,647 $4.3M No change
TARA Protara Therapeutic Inc. 1.01% 800,000 $4.2M New
GHRS GH Research PLC 0.96% 572,665 $4.0M No change
RLYB Rallybio Corp. 0.83% 3,630,724 $3.5M No change
SLN Silence Therapeutics PLC-ADR 0.78% 476,200 $3.3M No change
ADVM Adverum Biotechnologies Inc. 0.60% 541,666 $2.5M No change
ALEC Alector Inc. 0.45% 995,841 $1.9M New
MERSANA THERAPEUTICS INC 0.45% 1,305,000 $1.9M No change
CDTX Cidara Therapeutics Inc. 0.36% 56,725 $1.5M No change
ZNTL Zentalis Pharmaceuticals Inc. 0.35% 490,000 $1.5M No change

Portfolio Sells Q3 2024 → Q4 2024
DNTH Dianthus Therapeutics Inc. Reduce -16.6% 5.35% −1.62
VKTX Viking Therapeutics Inc. Reduce -20.2% 1.82% −1.29
COGT Cogent Biosciences Inc. Sold out 0.00% −1.25
CNTA Centessa Pharmaceuticals Ltd. Reduce -35.3% 3.32% −0.92
PRAX Praxis Precision Medicines I Reduce -50.0% 3.12% −0.92
ELVN Enliven Therapeutics Inc. Reduce -7.0% 8.75% −0.50
TECX Tectonic Therapeutic Inc. Reduce -7.7% 6.57% +2.53

Portfolio Buys Q3 2024 → Q4 2024
CAMP CAMP4 Therapeutics Corp. New 3.65% +3.65
AKRO Akero Therapeutics Inc. New 1.10% +1.10
TARA Protara Therapeutic Inc. New 1.01% +1.01
ALEC Alector Inc. New 0.45% +0.45

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 16$287.9MMPLT, TYRA, TRDA, PHVS, CAMP
Q1 2026 20$360.2MERAS, TRDA, TYRA, CAMP, CNTA
Q4 2025 21$318.1MTRDA, CAMP, TYRA, VRDN, PHVS
Q3 2025 25$273.0MSKYE, TRDA, PHVS, CAMP, CNTA
Q2 2025 29$260.1MSKYE, TRDA, DNTH, ELVN, PHVS
Q1 2025 31$264.4MTRDA, ELVN, DNTH, SKYE, PHVS
Q4 2024 31$419.1MTRDA, ELVN, SKYE, TECX, ARTV
Q3 2024 28$484.0MTRDA, ELVN, SKYE, ARTV, DNTH
Q2 2024 28$447.1MSKYE, TRDA, ELVN, DNTH, CLDX
Q1 2024 26$446.6MELVN, TRDA, DNTH, MRUS, CLDX